Product image of Munuza (Tobramycin) supplied by GNH India

Munuza

Active Ingredient:
Tobramycin
Origin:
EU

Munuza (Tobramycin)

Tobramycin, the active ingredient in Munuza, is an aminoglycoside antibiotic presented as an inhalation formulation for the treatment of chronic Pseudomonas aeruginosa lung infections in cystic fibrosis patients. It is indicated for patients with cystic fibrosis who experience persistent bacterial colonisation, helping to reduce exacerbations and improve lung function.

GNH India supplies Munuza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with all batches meeting EU pharmacopeial standards and delivered under strict quality assurance protocols.

Manufacturer / TM Owner

Aristo Pharma Gmbh (Art 57)

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Munuza (tobramycin) is used via inhalation to manage bacterial infections affecting the respiratory tract, particularly in cystic fibrosis.
  • Cystic fibrosis lung infection: decreases chronic Pseudomonas aeruginosa colonisation and helps maintain lung function.
  • Chronic Pseudomonas aeruginosa infection: lowers bacterial burden in the airways and reduces exacerbation rates.
  • Persistent respiratory infection in bronchiectasis: improves sputum clearance and reduces infection severity.
  • Pseudomonas aeruginosa colonisation in patients with chronic lung disease: assists in long‑term bacterial control.

How It Works

  • Tobramycin binds to the bacterial 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis. This disruption leads to rapid bactericidal activity against aerobic gram‑negative organisms such as Pseudomonas aeruginosa, particularly when delivered directly to the lungs via inhalation, allowing high local concentrations with limited systemic exposure. The drug’s affinity for the ribosomal binding site ensures selective targeting of bacterial cells while sparing human ribosomes.

Side Effects

Inhaled tobramycin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Cough or throat irritation
  • Dysphonia (hoarse voice)
  • Bronchospasm or wheezing
  • Metallic taste in the mouth

Serious or Rare Side Effects

  • Ototoxicity leading to hearing loss
  • Nephrotoxicity causing renal impairment
  • Severe allergic reactions, including anaphylaxis

Precautions & Warnings

Use of inhaled tobramycin requires careful monitoring to minimise risks.

  • Renal monitoring: assess kidney function before and during therapy.
  • Audiometric testing: evaluate hearing periodically due to risk of ototoxicity.
  • Respiratory assessment: monitor for bronchospasm and adjust inhalation technique as needed.
  • Hypersensitivity: discontinue if signs of allergic reaction appear.
  • Pregnancy and lactation: use only if benefits outweigh risks after consulting a prescriber.
  • Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Tobramycin can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid)

  • Loop diuretics (e.g., furosemide): increased risk of nephrotoxicity.
  • Other nephrotoxic agents (e.g., vancomycin, amphotericin B): additive kidney damage.
  • Neuromuscular blocking agents (e.g., curare): enhanced neuromuscular blockade.

Moderate Interactions (Monitor Closely)

  • Cisplatin: heightened ototoxic risk.
  • Fluoroquinolones: potential antagonistic effect on antibacterial activity.
  • Antacids containing magnesium or aluminum: may affect absorption if oral formulation is used.

Frequently Asked Questions

Munuza contains the aminoglycoside tobramycin and is indicated for inhalation treatment of chronic Pseudomonas aeruginosa lung infections in patients with cystic fibrosis. It helps reduce bacterial colonisation, lower the frequency of pulmonary exacerbations, and support overall lung function.

Tobramycin binds to the bacterial 30S ribosomal subunit, causing misreading of messenger RNA and blocking protein synthesis. This leads to rapid bacterial cell death, especially against gram‑negative organisms such as Pseudomonas aeruginosa, when delivered directly to the airways.

The dose of Munuza is determined by the prescribing clinician based on the patient’s age, weight, severity of infection, and renal function. Healthcare professionals tailor the inhalation regimen to achieve optimal lung concentrations while minimising systemic exposure.

Safety data for inhaled tobramycin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under the guidance of a qualified healthcare provider.

To place an order, submit an enquiry on the Munuza product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Munuza (tobramycin) is an aminoglycoside, whereas alternatives such as inhaled aztreonam belong to the monobactam class. Tobramycin offers a well‑established safety profile for CF patients and is effective against multidrug‑resistant Pseudomonas, while aztreonam may be preferred in patients with aminoglycoside intolerance.

Munuza should be stored at temperatures below 25 °C, protected from moisture and direct sunlight. Keep the product in its original packaging until use, and follow any manufacturer‑provided instructions for reconstitution or nebuliser preparation to maintain stability.

Munuza is administered by inhalation using a nebuliser or compatible inhalation device. The patient inhales the prescribed dose, typically twice daily, following the device’s cleaning and maintenance guidelines to ensure consistent drug delivery to the lungs.

The most serious adverse effects include ototoxicity, which can lead to permanent hearing loss, and nephrotoxicity, which may impair kidney function. Severe hypersensitivity reactions such as anaphylaxis and bronchospasm are also possible and require immediate medical attention.

Munuza is contraindicated in individuals with known hypersensitivity to tobramycin or other aminoglycosides. Patients with severe renal impairment, uncontrolled asthma, or a history of significant ototoxicity should avoid its use unless a specialist determines that benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tobramycin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT